This randomized controlled trial aims to evaluate the effect of polymethylmethacrylate dialysis membranes use on the intensity of pruritus in patients with CKD stage 5D receiving maintenance hemodialysis. The main question it aims to answer is: Does the use of polymethylmethacrylate (PMMA) membranes reduce the intensity of pruritus in dialysis patients? Researchers will compare PMMA membranes to standard polysulfone-based membranes to see if PMMA works to reduce moderate-to-severe pruritis and pruritis-related quality of life. Participants will: * receive maintenance hemodialysis with PMMA or polysulfone membranes for 2 months; * fill in questionnaires about intensity of pruritis and its impact on daily life.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
62
A polymethylmethacrylate hollow fiber membrane (PMMA membrane) has unique properties including the uniform structure and the adsorption property.
Dialyzers containing polysulfone membranes are widely used for modern dialysis therapies as they allow efficient removal of a broad spectrum of uremic toxins.
Saint Petersburg State University Hospital
Saint Petersburg, Russia
RECRUITING5D Elman Itch Scale total score
The 5-D itch scale is a reliable, multidimensional measure of itching that has been validated in patients with chronic pruritus to able to detect changes over time. This questionnaire was designed to be useful as an outcome measure in clinical trials. The five dimensions are degree, duration, direction, disability and distribution.
Time frame: From enrollment to the end of treatment at 8 weeks
WI-NRS score
24-hour Worst Itching Intensity Numerical Rating Scale
Time frame: From enrollment to the end of treatment at 8 weeks
Skindex-16 score
Multidimensional tool to assess pruritis
Time frame: From enrollment to the end of treatment at 8 weeks
Itch-MOS score
Itch-MOS questionnaire aims to evaluate impact of pruritis on sleep.
Time frame: From enrollment to the end of treatment at 8 weeks
5D Elman Itch Scale total score
Time frame: From the end of active treatment to the end of follow-up (4 weeks)
WI-NRS score
Time frame: From the end of active treatment to the end of follow-up (4 weeks)
Skindex-16 score
Time frame: From the end of active treatment to the end of follow-up (4 weeks)
Itch-MOS score
Time frame: From the end of active treatment to the end of follow-up (4 weeks)
C-reactive protein concentration
Time frame: From enrollment to the end of treatment at 8 weeks
Serum ferritin
Time frame: From enrollment to the end of treatment at 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.